Fortress Biotech Increases Stake in Avenue Therapeutics to 13.4% via Annual Equity Grant
ATXI has more than doubled off its 52-week low of $0.165 on light trading volume (0.1× avg).
Summary
Fortress Biotech, Inc. increased its beneficial ownership in Avenue Therapeutics to 13.4% following an annual equity grant, a routine event under a Founders Agreement.
Key Events · Ownership and Investor Activity · ATXI
-
Beneficial Ownership Increase
Fortress Biotech, Inc. increased its beneficial ownership in Avenue Therapeutics, Inc. to 13.4% of the outstanding common stock.
-
Annual Equity Grant
The increase resulted from an annual equity grant of 111,209 shares of common stock to Fortress Biotech, Inc. under a pre-existing Founders Agreement, valued at approximately $68,948.
-
Controlling Shareholder Status
Fortress Biotech, Inc. also holds all outstanding Class A preferred stock, which provides a voting majority and is convertible into common stock, indicating a controlling interest in the company.
Analysis · ATXI · Life Sciences
Fortress Biotech, Inc., a significant and controlling shareholder of Avenue Therapeutics, Inc., has increased its beneficial ownership to 13.4% through an annual equity grant. This grant of 111,209 common shares, valued at approximately $68,948, represents a substantial issuance relative to the company's small market capitalization. While dilutive to existing common shareholders, this transaction is part of a pre-existing Founders Agreement and reflects Fortress Biotech's ongoing, structured involvement and controlling interest in Avenue Therapeutics.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATXI was trading at $0.62 on OTC in the Life Sciences sector, with a market capitalization of approximately $2M. The 52-week trading range was $0.17 to $2.23. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.